Literature DB >> 18348466

Pharmacokinetics of huperzine A following oral administration to human volunteers.

Y X Li1, R Q Zhang, C R Li, X H Jiang.   

Abstract

The objective of the present study was to investigate the in vivo pharmacokinetics of huperzine A in healthy human volunteers. Twelve subjects (M 6, F 6; age ranged from 20-25 years) participated in the study. Huperzine A was administered in tablet form at a single dose of 0.4 mg. Following oral administration, the presence of huperzine A started to appear in the plasma at 5-10 min, and reached the peak concentrations with a Cmax of 2.59 +/- 0.37 ng/ml at 58.33 +/- 3.89 min (time to reach peak level, Tmax. The area under plasma vs time curve (AUC(0-t)) and the area under plasma from zero to infinity (AUC(0-infinity) for huperzine A were found to be 1986.96 +/- 164.57 microg/l.min and 2450.34 +/- 233.32 microg/l.min, respectively. The results of this study indicated that the pharmacokinetics of huperzine A conformed to a two-compartmental open model. The mean values of alpha and the beta half-life were 21.13 +/- 7.28 min and 716.25 +/- 130.18 min respectively, and showed a biphasic profile with rapid distribution followed by a slower elimination rate.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18348466     DOI: 10.1007/BF03191002

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  8 in total

Review 1.  Huperzine A (shuangyiping): a promising drug for Alzheimer's disease.

Authors:  X C Tang
Journal:  Zhongguo Yao Li Xue Bao       Date:  1996-11

2.  Pharmacokinetics of tablet huperzine A in six volunteers.

Authors:  B C Qian; M Wang; Z F Zhou; K Chen; R R Zhou; G S Chen
Journal:  Zhongguo Yao Li Xue Bao       Date:  1995-09

3.  [Effects of huperzine A on learning and the retrieval process of discrimination performance in rats].

Authors:  X C Tang; Y F Han; X P Chen; X D Zhu
Journal:  Zhongguo Yao Li Xue Bao       Date:  1986-11

4.  Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat.

Authors:  X C Tang; P De Sarno; K Sugaya; E Giacobini
Journal:  J Neurosci Res       Date:  1989-10       Impact factor: 4.164

5.  Simple determination of huperzine A in human plasma by liquid chromatographic-tandem mass spectrometric method.

Authors:  Yun-Xia Li; Xue-Hua Jiang; Ke Lan; Ling Wang
Journal:  Biomed Chromatogr       Date:  2007-01       Impact factor: 1.902

6.  A sensitive method for the determination of the novel cholinesterase inhibitor ZT-1 and its active metabolite huperzine A in rat blood using liquid chromatography/tandem mass spectrometry.

Authors:  Chuan Li; Feifei Du; Chen Yu; Xing Xu; Jiang Zheng; Fang Xu; Dayuan Zhu
Journal:  Rapid Commun Mass Spectrom       Date:  2004       Impact factor: 2.419

Review 7.  The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease.

Authors:  Andrea Zangara
Journal:  Pharmacol Biochem Behav       Date:  2003-06       Impact factor: 3.533

8.  Liquid chromatographic-tandem mass spectrometric method for the quantitation of huperzine A in dog plasma.

Authors:  Yingwu Wang; Dafeng Chu; Jingkai Gu; J Paul Fawcett; Yi Wu; Wanhui Liu
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2004-04-25       Impact factor: 3.205

  8 in total
  4 in total

1.  Population pharmacokinetic modeling and simulation of huperzine A in elderly Chinese subjects.

Authors:  Lei Sheng; Yi Qu; Jing Yan; Gang-Yi Liu; Wei-Liang Wang; Yi-Jun Wang; Hong-Yi Wang; Meng-Qi Zhang; Chuan Lu; Yun Liu; Jing-Yin Jia; Chao-Ying Hu; Xue-Ning Li; Chen Yu; Hong-Rong Xu
Journal:  Acta Pharmacol Sin       Date:  2016-05-16       Impact factor: 6.150

2.  Pharmacokinetics and tolerability of oral dosage forms of huperzine a in healthy Chinese male volunteers: a randomized, single dose, three-period, six-sequence crossover study.

Authors:  San-Lan Wu; Jun Gan; Jing Rao; Si-Jie He; Wen-Wen Zhu; Ying Zhao; Yong-Ning Lv; Jian-Geng Huang; Ya-Ni Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-10-20

3.  Alterations in the Timing of Huperzine A Cerebral Pharmacodynamics in the Acute Traumatic Brain Injury Setting.

Authors:  Ugur Damar; Roman Gersner; Joshua T Johnstone; Kush Kapur; Stephen Collins; Steven Schachter; Alexander Rotenberg
Journal:  J Neurotrauma       Date:  2017-11-21       Impact factor: 5.269

4.  Safety and Preliminary Efficacy of the Acetylcholinesterase Inhibitor Huperzine A as a Treatment for Cocaine Use Disorder.

Authors:  Richard De La Garza; Christopher D Verrico; Thomas F Newton; James J Mahoney; Daisy G Y Thompson-Lake
Journal:  Int J Neuropsychopharmacol       Date:  2015-09-12       Impact factor: 5.176

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.